AAPS PharmSciTech

, Volume 18, Issue 6, pp 1917–1924 | Cite as

Polymeric Nanofiber/Antifungal Formulations Using a Novel Co-extrusion Approach

  • Mohammad Mofidfar
  • Jia Wang
  • Lisa Long
  • Christopher L. Hager
  • Chairut Vareechon
  • Eric Pearlman
  • Eric Baer
  • Mahmoud GhannoumEmail author
  • Gary E. WnekEmail author
Research Article


We report the successful implementation of a novel melt co-extrusion process to fabricate ca. 1 μm diameter fibers of poly(caprolactone) (PCL) containing the antifungal compound clotrimazole in concentrations between 4 and 8 wt%. The process involves co-extrusion of a clotrimazole-loaded PCL along with poly(ethylene oxide) (PEO) as a co-feed, with subsequent removal of PEO to isolate PCL-clotrimazole fibers. In vitro tests of the clotrimazole-containing fibers against the fungus Aspergillus fumigatus, Candida albicans, and Trichophyton mentagrophytes strains demonstrated good antifungal activity which was maintained for more than 3 weeks. An in vivo study using a mouse model showed the lowest tissue fungal burden for PCL-clotrimazole when compared to a PCL-only patch and untreated controls. Comparative studies were conducted with clotrimazole-containing PCL fibers fabricated by electrospinning. Our data showed that the co-extruded, clotrimazole-containing fibers maintain activity for longer times vs. electrospun samples. This, coupled with the much higher throughput of the co-extrusion process vs. electrospinning, renders this new approach very attractive for the fabrication of drug-releasing polymer fibers.


antifungal release clotrimazole co-extruded fiber poly(caprolactone) 



The authors acknowledge funding from the National Science Foundation (NSF) Science and Technology Center, the Center for Layered Polymeric Systems (CLiPS), under Grant DMR-0423914, and the NSF under Grant CMMI-1335276. We are also grateful for discussions with Dr. Andrew Olah of CLiPS.


  1. 1.
    Muffly TM, Tizzano AP, Walters MD. The history and evolution of sutures in pelvic surgery. J R Soc Med. 2011;104:107–12.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kenawy E-R, Bowlin GL, Mansfield K, Layman J, Simpson DG, Sanders EH, et al. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release. 2002;81:57–64.CrossRefGoogle Scholar
  3. 3.
    Zamani M, Prabhakaran MP, Ramakrishna S. Advances in drug delivery via electrospun and electrosprayed nanomaterials. Int J Nanomedicine. 2013;8:2997–3017.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Agarwal S, Wendorff JH, Greiner A. Use of electrospinning technique for biomedical applications. Polymer. 2008;49:5603–21.CrossRefGoogle Scholar
  5. 5.
    Mir AS, Garg T, Vaidya B, Goyal AK, Rath G. Development and characterization of clotrimazole loaded electrospun nanofibers for the management of oral candidiasis. J Nanopharm Drug Deliv. 2014;2:192–8.CrossRefGoogle Scholar
  6. 6.
    Wang J, Langhe D, Ponting M, Wnek GE, Korley LTJ, Baer E. Manufacturing of polymer continuous nanofibers using a novel co-extrusion and multiplication technique. Polymer. 2014;55:673–85.CrossRefGoogle Scholar
  7. 7.
    Shah S, Maddineni S, Lu J, Repka MA. Melt extrusion with poorly soluble drugs. Int J Pharm. 2013;453:233–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Repka MA, Repka SL, McGinity JW. Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof. US Patent. 2002;6(375):963.Google Scholar
  9. 9.
    Prodduturi S, Urman KL, Otaigbe JU, Repka MA. Stabilization of hot-melt extrusion formulations containing solid solutions using polymer blends. AAPS PharmSciTech. 2007;8:152–61.CrossRefGoogle Scholar
  10. 10.
    Repka MA, Majumdar S, Battu SK, Srirangam R, Upadhye SB. Applications of hot-melt extrusion for drug delivery. Expert Opin Drug Deliv. 2008;5:1357–76.CrossRefPubMedGoogle Scholar
  11. 11.
    Repka MA, Prodduturi S, Stodghill SP. Production and characterization of hot-melt extruded films containing clotrimazole. Drug Dev Ind Pharm. 2003;29:757–65.CrossRefPubMedGoogle Scholar
  12. 12.
    Kim S-E, Wang J, Jordan A, Korley LTJ, Baer E, Pokorski J. Surface modification of melt extruded poly(ε-caprolactone) nanofibers: toward a new scalable biomaterial scaffold. ACS Macro Lett. 2014;3:585–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Baer E, Langhe D, Wang J. Production of micro- and nano-fibers by continuous microlayer coextrusion. Patent Appl. 2013; WO2013155519 A1.Google Scholar
  14. 14.
    Jordan AM, Korley LTJ. Toward a tunable fibrous scaffold: structural development during uniaxial drawing of coextruded poly(caprolactone) fibers. Macromolecules. 2015;48:2614–27.CrossRefGoogle Scholar
  15. 15.
    Jordan AM, Marotta T, Korley LTJ. Reducing environmental impact: solvent and PEO reclamation during production of melt-extruded PCL nanofibers. ACS Sustain Chem Eng. 2015;3:2994–3003.CrossRefGoogle Scholar
  16. 16.
    Liu RYF, Jin Y, Hiltner A, Baer E. Probing nanoscale polymer interactions by forced- assembly. Macromol Rapid Commun. 2003;24:943–8.CrossRefGoogle Scholar
  17. 17.
    Ponting M, Hiltner A, Baer E. Polymer nanostructures by forced assembly: process, structure, and properties. Macromol Symp. 2010;294:19–32.CrossRefGoogle Scholar
  18. 18.
    Lamba H, Mofidfar M, Emancipator S, Wnek G, Elgudin Y. Development of tissue engineered small diameter vascular grafts, TERMIS World Congress, Boston, MA, September 8-11. 2015: 248–249.Google Scholar
  19. 19.
    Espinel-Ingroff A, Ostrosky-Zeichner L, Schell W, Gibbs DL, Wang A, Turnidge J, et al. Quality control guidelines for amphotericin B, itraconazole, posaconazole, and voriconazole disk diffusion susceptibility tests with nonsupplemented Mueller-Hinton agar (CLSI M51-A Document) for nondermatophyte. J Clin Microbiol. 2011;49:2568–71.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tatsumi Y, Yokoo M, Arika T, Yamaguchi H. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother. 2001;45:1493–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Development of in vitro susceptibility testing criteria and quality control parameters; approved guide-line, 3rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute Villanova, PA. 2008.Google Scholar
  22. 22.
    Guide for the Care and Use of Laboratory Animals, 8th edition. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academies Press (US). 2011.Google Scholar
  23. 23.
    Ponting M, Lin Y, Keum JK, Hiltner A, Baer E. Effect of substrate on the isothermal crystallization kinetics of confined poly(ε-caprolactone) nanolayers. Macromolecules. 2010;43(20):8619–27.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2016

Authors and Affiliations

  • Mohammad Mofidfar
    • 1
  • Jia Wang
    • 1
  • Lisa Long
    • 2
    • 3
  • Christopher L. Hager
    • 2
    • 3
  • Chairut Vareechon
    • 4
  • Eric Pearlman
    • 5
  • Eric Baer
    • 1
  • Mahmoud Ghannoum
    • 2
    • 3
    Email author
  • Gary E. Wnek
    • 1
    Email author
  1. 1.Department of Macromolecular Science and EngineeringCase Western Reserve UniversityClevelandUSA
  2. 2.Department of Dermatology and Center for Medical MycologyCase Western Reserve UniversityClevelandUSA
  3. 3.University Hospitals Case Medical CenterClevelandUSA
  4. 4.Department of Ophthalmology and Visual ScienceCase Western Reserve UniversityClevelandUSA
  5. 5.Institute for Immunology, Physiology & Biophysics, School of MedicineUniversity of CaliforniaIrvineUSA

Personalised recommendations